Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.00T
Market cap1.00T
Price-Earnings ratio
38.34
Price-Earnings ratio38.34
Dividend yield
0.58%
Dividend yield0.58%
Average volume
2.96M
Average volume2.96M
High today
$1,070.34
High today$1,070.34
Low today
$1,047.07
Low today$1,047.07
Open price
$1,049.45
Open price$1,049.45
Volume
3.47M
Volume3.47M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,064.59, giving the company a market capitalization of 1T. It carries a P/E multiple of 38.34 and pays a dividend yield of 58.5%.

On 2026-05-26, Eli Lilly(LLY) stock traded between a low of $1,047.07 and a high of $1,070.34. Shares are currently priced at $1,064.59, which is +1.7% above the low and -0.5% below the high.

The Eli Lilly(LLY)'s current trading volume is 3.47M, compared to an average daily volume of 2.96M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Simply Wall St 3h
A Look At Eli Lilly Valuation After Retatrutide’s Strong Phase 3 Obesity Trial Results

Eli Lilly (LLY) is back in the spotlight after its investigational obesity drug retatrutide hit strong Phase 3 trial milestones, showing high and durable weight...

A Look At Eli Lilly Valuation After Retatrutide’s Strong Phase 3 Obesity Trial Results
Nasdaq 6h
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

Key Points Eli Lilly just reported strong results for a next-generation GLP-1 drug that it is developing. GLP-1 developments in India aren't headline-grabbing...

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
TipRanks 13h
Eli Lilly announces Phase 1b Heart-2 study results for Verve-102

Eli Lilly (LLY) and Company announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durabl...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

The Motley Fool 20h
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.

When you think of growth stocks, you may immediately think of technology. But this isn't the only field delivering significant revenue gains these days. In fact...

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
TipRanks 4d
Eli Lilly Expands Heart Failure Pipeline With New Phase 1 Trial of LY3971297

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligen...

TipRanks 4d
Eli Lilly’s Remternetug Study Reaches Completion, Setting the Stage in Alzheimer’s Drug Race

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligen...

TipRanks 4d
Lilly’s Tirzepatide Ramadan Study Nears Data Phase, Eyeing a Key Diabetes Market Segment

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligen...

TipRanks 4d
Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion

Eli Lilly And Company (LLY), Rigel Pharmaceuticals (RIGL) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, dat...

Simply Wall St 4d
Is It Too Late To Consider Eli Lilly After Its Recent Share Price Surge?

Wondering whether Eli Lilly's share price still reflects fair value, or if expectations have started to run ahead of the fundamentals? This article breaks down...

Is It Too Late To Consider Eli Lilly After Its Recent Share Price Surge?
Benzinga 4d
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss

The study evaluated retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways, in adults with obesity or overweight and at leas...

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.